Amgen

Otezla (apremilast) is a PDE4 inhibitor from Amgen that raises levels of cyclic AMP inside immune cells, dialling down the inflammatory chemicals that drive psoriatic arthritis, plaque psoriasis, and oral ulcers in Behçet's disease. It is taken by mouth and does not require routine laboratory monitoring for organ toxicity.

Apremilast is a tablet that works inside immune cells. It blocks an enzyme called PDE4, which normally breaks down a molecule called cAMP. With PDE4 b

Carfilzomib (Kyprolis) is a proteasome inhibitor that blocks the cell's waste-disposal system. Cancer cells, especially multiple myeloma cells, produce large amounts of waste proteins; when the proteasome is blocked, these waste proteins build up and the cancer cells die. It is used alone or in combination to treat multiple myeloma.

Carfilzomib blocks the action of the proteasome, a structure inside cells that breaks down old or damaged proteins. Multiple myeloma cells produce lar

Denosumab is a RANKL inhibitor from Amgen. As Prolia it strengthens bones in osteoporosis; under oncology brands it prevents skeletal complications of cancer that has spread to bone. It works by slowing the cells that break bone down.

Bones stay healthy through a balance between new bone being made and old bone being broken down by cells called osteoclasts. RANKL is the signal that

Aimovig (erenumab) is a monoclonal antibody from Amgen that blocks the receptor for calcitonin gene-related peptide (CGRP), a key signaling molecule in migraine. Given once monthly by injection, it prevents migraine attacks in adults.

Erenumab is an antibody that targets the receptor for calcitonin gene-related peptide (CGRP), a small protein released during migraine attacks. CGRP c

Repatha (evolocumab) is a PCSK9 inhibitor from Amgen. By protecting LDL receptors from destruction, it dramatically lowers LDL cholesterol and reduces major cardiovascular events in adults at increased risk.

LDL cholesterol is removed from the blood by receptors on liver cells. A protein called PCSK9 causes those receptors to be broken down, limiting how m

Evenity (romosozumab) is a sclerostin inhibitor from Amgen. Given as monthly injections for up to 12 months, it builds new bone and also slows bone breakdown, reducing fracture risk in postmenopausal women with severe osteoporosis.

Romosozumab is an antibody that targets a protein called sclerostin, which normally holds back bone formation. By blocking sclerostin, the medicine st

Lumakras (sotorasib) is a first-in-class oral KRAS G12C inhibitor from Amgen for adults with advanced non-small cell lung cancer or metastatic colorectal cancer that carry the KRAS G12C mutation. It locks the mutant KRAS protein in an inactive state, switching off the growth signal that drives these tumours.

Sotorasib targets a specific broken version of the KRAS protein called KRAS G12C, which is found in some lung and colorectal cancers. Normal KRAS acts